MA33304B1 - Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase - Google Patents
Indazoles substitués par oxazole comme inhibiteurs de pi3-kinaseInfo
- Publication number
- MA33304B1 MA33304B1 MA34398A MA34398A MA33304B1 MA 33304 B1 MA33304 B1 MA 33304B1 MA 34398 A MA34398 A MA 34398A MA 34398 A MA34398 A MA 34398A MA 33304 B1 MA33304 B1 MA 33304B1
- Authority
- MA
- Morocco
- Prior art keywords
- oxazole
- kinase inhibitors
- substituted indazoles
- compounds
- indazoles
- Prior art date
Links
- 150000002473 indoazoles Chemical class 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17403309P | 2009-04-30 | 2009-04-30 | |
| PCT/EP2010/055666 WO2010125082A1 (en) | 2009-04-30 | 2010-04-28 | Oxazole substituted indazoles as pi3-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33304B1 true MA33304B1 (fr) | 2012-05-02 |
Family
ID=42225106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34398A MA33304B1 (fr) | 2009-04-30 | 2010-04-28 | Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase |
Country Status (39)
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| ES2445199T3 (es) * | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
| JP5502077B2 (ja) * | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| CN102459253B (zh) * | 2009-04-30 | 2015-03-25 | 葛兰素集团有限公司 | 作为pi3-激酶抑制剂的*唑取代的吲唑化合物 |
| CN102372675B (zh) * | 2010-08-14 | 2013-12-18 | 王娜 | 6-氯-4-碘吲唑及其制备方法与应用 |
| US9102668B2 (en) * | 2010-09-08 | 2015-08-11 | Glaxo Group Limited | Polymorphs and salts |
| WO2012032065A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| JP5965402B2 (ja) * | 2010-09-08 | 2016-08-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| JP6063870B2 (ja) * | 2010-11-08 | 2017-01-18 | ライセラ・コーポレイション | ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 |
| CA2857302C (en) | 2011-12-15 | 2020-08-25 | Novartis Ag | Use of inhibitors of the activity or function of pi3k |
| RU2014149136A (ru) | 2012-05-08 | 2016-07-10 | Мерк Шарп И Доум Корп. | ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| WO2013169864A2 (en) | 2012-05-08 | 2013-11-14 | Lycera Corporation | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE |
| EP2872143B1 (en) * | 2012-07-16 | 2017-12-13 | Neuropore Therapies, Inc. | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation |
| US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| JPWO2014098232A1 (ja) * | 2012-12-21 | 2017-01-12 | 学校法人東京理科大学 | Ｐｉ３キナーゼ阻害剤を含む医薬組成物、ビタミンｄ受容体に作用する化合物を含む医薬組成物、凍結乾燥組成物、凍結乾燥組成物の製造方法、及び経肺投与用医薬組成物 |
| EP3057587A1 (en) | 2013-10-17 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
| US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
| US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
| SG11201605917SA (en) * | 2014-01-24 | 2016-08-30 | Abbvie Inc | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use |
| MX2016010998A (es) | 2014-02-27 | 2017-03-31 | Lycera Corp | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. |
| US10226376B2 (en) | 2014-03-19 | 2019-03-12 | Purewick Corporation | Apparatus and methods for receiving discharged urine |
| US10952889B2 (en) | 2016-06-02 | 2021-03-23 | Purewick Corporation | Using wicking material to collect liquid for transport |
| US11806266B2 (en) | 2014-03-19 | 2023-11-07 | Purewick Corporation | Apparatus and methods for receiving discharged urine |
| US10390989B2 (en) | 2014-03-19 | 2019-08-27 | Purewick Corporation | Apparatus and methods for receiving discharged urine |
| US11376152B2 (en) | 2014-03-19 | 2022-07-05 | Purewick Corporation | Apparatus and methods for receiving discharged urine |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| US9127069B1 (en) * | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
| CN104086538B (zh) * | 2014-06-13 | 2016-07-06 | 南京药石科技股份有限公司 | 一种pi3k激酶抑制剂的中间体及其制备方法与应用 |
| WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
| GB201509492D0 (en) * | 2015-06-02 | 2015-07-15 | Glaxosmithkline Ip Dev Ltd | Novel processes |
| HK1253734A1 (zh) | 2015-06-11 | 2019-06-28 | The Regents Of The University Of Michigan | 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物 |
| JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
| CA3002850A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
| AU2016344111A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| WO2017123058A1 (en) * | 2016-01-14 | 2017-07-20 | Handok Inc. | Compounds antagonizing a3 adenosine receptor, method for preparing them, and medical-use thereof |
| US10376406B2 (en) | 2016-07-27 | 2019-08-13 | Purewick Corporation | Male urine collection device using wicking material |
| JP2019524792A (ja) * | 2016-08-08 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化合物 |
| CN110612075B (zh) | 2017-01-31 | 2022-09-09 | 普利维克公司 | 用于接收排出的尿液的装置和方法 |
| CA3098676C (en) | 2018-05-01 | 2024-04-16 | Purewick Corporation | Fluid collection devices, related systems, and related methods |
| EP3787567A1 (en) | 2018-05-01 | 2021-03-10 | Purewick Corporation | Fluid collection devices, systems, and methods |
| JP7129493B2 (ja) | 2018-05-01 | 2022-09-01 | ピュアウィック コーポレイション | 流体収集デバイス、及び関連のシステム |
| KR102492111B1 (ko) | 2018-05-01 | 2023-01-27 | 퓨어윅 코포레이션 | 유체 수집 장치 및 이를 사용하는 방법 |
| WO2021138414A1 (en) | 2020-01-03 | 2021-07-08 | Purewick Corporation | Urine collection devices having a relatively wide portion and an elongated portion and related methods |
| EP4125746B1 (en) | 2020-03-26 | 2024-05-15 | Purewick Corporation | Multi-layered urine capture device and related methods |
| WO2021211801A1 (en) | 2020-04-17 | 2021-10-21 | Purewick Corporation | Fluid collection assemblies including a fluid impermeable barrier having a sump and a base |
| US12472090B2 (en) | 2020-04-17 | 2025-11-18 | Purewick Corporation | Female external catheter devices having a urethral cup, and related systems and methods |
| WO2021211729A1 (en) | 2020-04-17 | 2021-10-21 | Purewick Corporation | Fluid collection devices, systems, and methods securing a protruding portion in position for use |
| US12491104B2 (en) | 2020-04-20 | 2025-12-09 | Purewick Corporation | Fluid collection devices adjustable between a vacuum-based orientation and a gravity-based orientation, and related systems and methods |
| US12048643B2 (en) | 2020-05-27 | 2024-07-30 | Purewick Corporation | Fluid collection assemblies including at least one inflation device and methods and systems of using the same |
| WO2022031943A1 (en) | 2020-08-06 | 2022-02-10 | Purewick Corporation | A fluid collection system including a garment and a fluid collection device |
| US12350187B2 (en) | 2020-08-11 | 2025-07-08 | Purewick Corporation | Fluid collection assemblies defining waist and leg openings |
| WO2022055957A1 (en) | 2020-09-09 | 2022-03-17 | Purewick Corporation | Fluid collection devices, systems, and methods |
| US11801186B2 (en) | 2020-09-10 | 2023-10-31 | Purewick Corporation | Urine storage container handle and lid accessories |
| CN116438200A (zh) | 2020-09-10 | 2023-07-14 | 普雷西里克斯公司 | 针对fap的抗体片段 |
| US12042423B2 (en) | 2020-10-07 | 2024-07-23 | Purewick Corporation | Fluid collection systems including at least one tensioning element |
| US12208031B2 (en) | 2020-10-21 | 2025-01-28 | Purewick Corporation | Adapters for fluid collection devices |
| US12257174B2 (en) | 2020-10-21 | 2025-03-25 | Purewick Corporation | Fluid collection assemblies including at least one of a protrusion or at least one expandable material |
| US12569365B2 (en) | 2020-10-21 | 2026-03-10 | Purewick Corporation | Fluid collection assemblies including at least one shape memory material disposed in the conduit |
| US12440370B2 (en) | 2020-10-21 | 2025-10-14 | Purewick Corporation | Apparatus with compressible casing for receiving discharged urine |
| US12048644B2 (en) | 2020-11-03 | 2024-07-30 | Purewick Corporation | Apparatus for receiving discharged urine |
| US12268627B2 (en) | 2021-01-06 | 2025-04-08 | Purewick Corporation | Fluid collection assemblies including at least one securement body |
| WO2022150463A1 (en) | 2021-01-07 | 2022-07-14 | Purewick Corporation | Wheelchair securable urine collection systems and related methods |
| JP7500744B2 (ja) | 2021-01-19 | 2024-06-17 | ピュアウィック コーポレイション | 可変流体収集デバイス、システム、及び方法 |
| WO2022182385A1 (en) | 2021-02-26 | 2022-09-01 | Purewick Corporation | Fluid collection devices having a sump between a tube opening and a barrier, and related systems and methods |
| US12551385B2 (en) | 2021-03-05 | 2026-02-17 | Purewick Corporation | Fluid collection assembly including a tube having porous wicking material for improved fluid transport |
| US12029677B2 (en) | 2021-04-06 | 2024-07-09 | Purewick Corporation | Fluid collection devices having a collection bag, and related systems and methods |
| US12251333B2 (en) | 2021-05-21 | 2025-03-18 | Purewick Corporation | Fluid collection assemblies including at least one inflation device and methods and systems of using the same |
| US12324767B2 (en) | 2021-05-24 | 2025-06-10 | Purewick Corporation | Fluid collection assembly including a customizable external support and related methods |
| US12150885B2 (en) | 2021-05-26 | 2024-11-26 | Purewick Corporation | Fluid collection system including a cleaning system and methods |
| US12575960B2 (en) | 2021-06-24 | 2026-03-17 | Purewick Corporation | Urine collection systems having one or more of volume, pressure, or flow indicators, and related methods |
| US12551366B2 (en) | 2021-08-02 | 2026-02-17 | Purewick Corporation | Fluid collection devices having multiple fluid collection regions, and related systems and methods |
| CA3244639A1 (en) | 2021-12-28 | 2025-06-13 | Nippon Shinyaku Co., Ltd. | Indazole compound and pharmaceutical |
| JP2025504577A (ja) * | 2022-01-31 | 2025-02-12 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 塩結晶 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| JP2025517625A (ja) | 2022-05-02 | 2025-06-10 | プレシリックス・ナームローゼ・ベンノートシヤープ | プレターゲティング |
Family Cites Families (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| CA2133439C (en) | 1992-04-02 | 2005-07-26 | Siegfried Benjamin Christensen, Iv | Compounds useful for treating allergic and inflammatory diseases |
| SI0765308T1 (sl) | 1994-06-15 | 2000-08-31 | The Wellcome Foundation Limited | Encimski inhibitorji |
| DE69637257T2 (de) | 1995-04-14 | 2008-06-12 | Smithkline Beecham Corp. | Verfahren zur Herstellung eines Dosierinhalators |
| US5821243A (en) | 1996-07-22 | 1998-10-13 | Viropharma Incorporated | Compounds compositions and methods for treating influenza |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| AU3328499A (en) | 1998-03-14 | 1999-10-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| WO2000066590A2 (en) | 1999-05-04 | 2000-11-09 | Ligand Pharmaceuticals, Inc. | Tetracyclic progesterone receptor modulator compounds and methods |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| PT1305329E (pt) | 2000-08-05 | 2007-12-24 | Glaxo Group Ltd | Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório |
| CA2423251A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002067683A1 (en) | 2001-02-26 | 2002-09-06 | Merck & Co., Inc. | Hiv protease inhibitors supported on cation exchange resins for oral administration |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| HUP0303829A3 (en) | 2001-04-16 | 2006-02-28 | Tanabe Seiyaku Co | Large conductance calcium-acitvated k channel opener compounds, use thereof and pharmaceutical compositions containing them |
| MY137522A (en) | 2001-04-30 | 2009-02-27 | Glaxo Group Ltd | Novel anti-inflammatory androstane derivatives. |
| ES2307751T3 (es) | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
| US7498352B2 (en) | 2001-06-26 | 2009-03-03 | Takeda Pharmaceutical Company Limited | TGF-β superfamily production/secretion promoter |
| RU2312854C2 (ru) | 2001-09-14 | 2007-12-20 | Глаксо Груп Лимитед | Производные фенэтаноламина для лечения респираторных заболеваний |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| WO2003051847A1 (en) | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
| ATE346058T1 (de) | 2002-01-14 | 2006-12-15 | Boehringer Ingelheim Pharma | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon |
| AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| US7268152B2 (en) | 2002-03-26 | 2007-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| HRP20040887A2 (en) | 2002-03-26 | 2005-04-30 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| ATE496620T1 (de) | 2002-04-11 | 2011-02-15 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
| DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| AU2003233780A1 (en) | 2002-06-27 | 2004-01-19 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
| AU2003281355A1 (en) | 2002-07-08 | 2004-01-23 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| AU2003251970A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| AU2003268064A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| KR20050033070A (ko) | 2002-08-09 | 2005-04-08 | 아스트라제네카 에이비이 | 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸 |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| MXPA05002887A (es) | 2002-09-16 | 2005-05-27 | Glaxo Group Ltd | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa. |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| EP1542996A4 (en) | 2002-09-20 | 2009-11-18 | Merck & Co Inc | OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR |
| ES2312843T3 (es) * | 2002-09-30 | 2009-03-01 | Bayer Healthcare Ag | Derivados de azolpirimidina condensados. |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| EP1556342B1 (en) | 2002-10-28 | 2008-03-26 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| WO2005016245A2 (en) | 2003-06-13 | 2005-02-24 | Zentaris Gmbh | Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| GB0320197D0 (en) * | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
| DE602004030930D1 (de) | 2003-10-14 | 2011-02-17 | Glaxo Group Ltd | Muscarinische acetylcholin-rezeptor-antagonisten |
| US7563906B2 (en) * | 2003-10-15 | 2009-07-21 | Ube Industries, Ltd. | Indazole derivatives |
| PL1699512T3 (pl) | 2003-11-03 | 2012-11-30 | Glaxo Group Ltd | Urządzenie do dozowania płynów |
| TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| WO2005058892A1 (en) | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| US20080227772A1 (en) | 2004-02-04 | 2008-09-18 | Neurosearch A/S | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands |
| GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| AU2005223351A1 (en) | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor |
| GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| AR050902A1 (es) | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
| CA2570637A1 (en) | 2004-06-24 | 2006-02-02 | Wenqing Yao | N-substituted piperidines and their use as pharmaceuticals |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| US20060013540A1 (en) * | 2004-07-19 | 2006-01-19 | Chao Zhang | Single fiber optical transceiver module |
| WO2006135383A2 (en) | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| BRPI0518222A (pt) | 2004-10-19 | 2008-11-04 | Hoffmann La Roche | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos |
| BRPI0518281A2 (pt) | 2004-11-18 | 2008-11-18 | Incyte Corp | inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos |
| JP2008521831A (ja) | 2004-11-30 | 2008-06-26 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| EP1841780B1 (en) | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
| WO2006089076A2 (en) | 2005-02-18 | 2006-08-24 | Neurogen Corporation | Thiazole amides, imidazole amides and related analogues |
| CA2602797A1 (en) | 2005-03-31 | 2007-02-15 | Ronen Kahana | Creating poultry and other animals resistant to viral disease |
| US20060264433A1 (en) | 2005-05-23 | 2006-11-23 | Backes Bradley J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| TW200800946A (en) * | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Substituted piperazines as metabotropic glutamate receptor antagonists |
| BRPI0614801A2 (pt) | 2005-08-16 | 2009-05-19 | Genzyme Corp | compostos de ligação a receptor de quimiocina |
| JPWO2007105637A1 (ja) | 2006-03-10 | 2009-07-30 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| JP2009531443A (ja) | 2006-03-29 | 2009-09-03 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | α−シヌクレイン毒性の抑制 |
| CN101437519A (zh) | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
| KR101499783B1 (ko) * | 2006-04-04 | 2015-03-09 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| WO2008020229A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
| CN101541758A (zh) | 2006-08-25 | 2009-09-23 | 艾博特公司 | 抑制trpv1的吲唑衍生物及其用途 |
| US7948877B2 (en) * | 2006-09-07 | 2011-05-24 | Via Technologies, Inc. | Systems and methods for packet forward control |
| EP2104671A2 (en) | 2006-09-25 | 2009-09-30 | Mutabilis SA | Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors |
| RU2009115954A (ru) | 2006-09-29 | 2010-11-10 | Новартис АГ (CH) | Пиразолопиримидины в качестве ингибиторов липидной киназы р13к |
| TWI405763B (zh) | 2006-11-02 | 2013-08-21 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| JP2010116389A (ja) * | 2008-10-17 | 2010-05-27 | Bayer Cropscience Ag | 殺虫性アリールピロリジン類 |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| EP2170884A2 (en) | 2007-06-25 | 2010-04-07 | Boehringer Ingelheim International GmbH | Chemical compounds |
| US8575156B2 (en) * | 2007-07-26 | 2013-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| JP5736171B2 (ja) | 2007-09-24 | 2015-06-17 | ジェネンテック， インコーポレイテッド | チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法 |
| JP2009127226A (ja) * | 2007-11-21 | 2009-06-11 | Seiji Ohara | 温水プールに雪を落し込む手段を持つ融雪装置 |
| EP2291373B1 (en) * | 2008-05-01 | 2013-09-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2009134387A1 (en) * | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| TW201004945A (en) * | 2008-05-01 | 2010-02-01 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| NZ588954A (en) | 2008-05-01 | 2012-08-31 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP5502077B2 (ja) * | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
| WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| ES2566339T3 (es) * | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
| ES2445199T3 (es) | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
| KR101665727B1 (ko) * | 2008-06-11 | 2016-10-12 | 하마마츠 포토닉스 가부시키가이샤 | 유리 용착 방법 |
| CN104327062A (zh) * | 2008-07-25 | 2015-02-04 | 贝林格尔·英格海姆国际有限公司 | 11β-羟基类固醇脱氢酶1的环状抑制剂 |
| US8245111B2 (en) * | 2008-12-09 | 2012-08-14 | Intel Corporation | Performing multi-bit error correction on a cache line |
| US20110237633A1 (en) | 2008-12-11 | 2011-09-29 | Bijoy Panicker | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| WO2010083163A1 (en) | 2009-01-13 | 2010-07-22 | Philadelphia Health And Education Corporation | The role of p110 delta signaling in morbidity and lung pathology induced by influenza virus infection |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| MA33216B1 (fr) * | 2009-04-30 | 2012-04-02 | Boehringer Ingelheim Int | Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1 |
| CN102459197B (zh) * | 2009-04-30 | 2015-08-19 | Abbvie公司 | 适用于治疗响应血清素5-ht6受体的调节的病症的n-苯基-(哌嗪基或高哌嗪基)-苯磺酰胺或苯磺酰基-苯基-(哌嗪或高哌嗪)化合物 |
| US8343959B2 (en) * | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| GEP20156309B (en) | 2009-04-30 | 2015-07-10 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CN102414175A (zh) * | 2009-04-30 | 2012-04-11 | 拜耳作物科学公司 | 杀虫的芳基吡咯烷 |
| CN102459253B (zh) | 2009-04-30 | 2015-03-25 | 葛兰素集团有限公司 | 作为pi3-激酶抑制剂的*唑取代的吲唑化合物 |
| EP2507223A1 (en) * | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| US20120238559A1 (en) * | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
| WO2011067366A1 (en) * | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
| WO2012032065A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| US9102668B2 (en) | 2010-09-08 | 2015-08-11 | Glaxo Group Limited | Polymorphs and salts |
| JP5965402B2 (ja) | 2010-09-08 | 2016-08-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| US10642898B1 (en) * | 2017-04-11 | 2020-05-05 | Northrop Grumman Systems Corporation | Three-dimensional graph |
-
2010
- 2010-04-28 CN CN201080030329.2A patent/CN102459253B/zh active Active
- 2010-04-28 US US12/768,777 patent/US8580797B2/en not_active Expired - Fee Related
- 2010-04-28 PT PT141948661T patent/PT2899191T/pt unknown
- 2010-04-28 DK DK10714892.6T patent/DK2424864T3/en active
- 2010-04-28 RS RS20150107A patent/RS53830B1/sr unknown
- 2010-04-28 HU HUE14194866A patent/HUE034724T2/hu unknown
- 2010-04-28 DK DK14194866.1T patent/DK2899191T3/da active
- 2010-04-28 ES ES17182412T patent/ES2876933T3/es active Active
- 2010-04-28 AU AU2010243613A patent/AU2010243613B2/en not_active Ceased
- 2010-04-28 HR HRP20150173TT patent/HRP20150173T1/hr unknown
- 2010-04-28 RS RS20171020A patent/RS56433B1/sr unknown
- 2010-04-28 TW TW104135940A patent/TWI562992B/zh not_active IP Right Cessation
- 2010-04-28 UY UY0001032585A patent/UY32585A/es not_active Application Discontinuation
- 2010-04-28 TW TW103127990A patent/TWI516487B/zh not_active IP Right Cessation
- 2010-04-28 ME MEP-2015-22A patent/ME02053B/me unknown
- 2010-04-28 EP EP10714892.6A patent/EP2424864B1/en active Active
- 2010-04-28 KR KR1020117028746A patent/KR101679642B1/ko not_active Expired - Fee Related
- 2010-04-28 JP JP2012507720A patent/JP5570589B2/ja not_active Expired - Fee Related
- 2010-04-28 PT PT107148926T patent/PT2424864E/pt unknown
- 2010-04-28 US US12/768,775 patent/US8575162B2/en not_active Expired - Fee Related
- 2010-04-28 MY MYPI2011005217A patent/MY160454A/en unknown
- 2010-04-28 SI SI201030873T patent/SI2424864T1/sl unknown
- 2010-04-28 MA MA34398A patent/MA33304B1/fr unknown
- 2010-04-28 LT LTEP14194866.1T patent/LT2899191T/lt unknown
- 2010-04-28 US US13/266,254 patent/US20120046286A1/en not_active Abandoned
- 2010-04-28 UA UAA201112776A patent/UA101098C2/uk unknown
- 2010-04-28 SG SG2011077989A patent/SG175782A1/en unknown
- 2010-04-28 NZ NZ596071A patent/NZ596071A/en not_active IP Right Cessation
- 2010-04-28 ES ES10714892T patent/ES2531274T3/es active Active
- 2010-04-28 AR ARP100101429A patent/AR076435A1/es active IP Right Grant
- 2010-04-28 PL PL10714892T patent/PL2424864T3/pl unknown
- 2010-04-28 SM SM20170481T patent/SMT201700481T1/it unknown
- 2010-04-28 JO JOP/2010/0132A patent/JO3025B1/ar active
- 2010-04-28 CA CA2759476A patent/CA2759476C/en active Active
- 2010-04-28 EP EP17182412.1A patent/EP3260453B1/en active Active
- 2010-04-28 KR KR1020167032300A patent/KR101771193B1/ko not_active Expired - Fee Related
- 2010-04-28 ME MEP-2017-242A patent/ME02900B/me unknown
- 2010-04-28 WO PCT/EP2010/055666 patent/WO2010125082A1/en not_active Ceased
- 2010-04-28 ES ES14194866.1T patent/ES2644724T3/es active Active
- 2010-04-28 EA EA201190227A patent/EA021056B1/ru not_active IP Right Cessation
- 2010-04-28 TW TW99113559A patent/TWI466884B/zh not_active IP Right Cessation
- 2010-04-28 PE PE2011001881A patent/PE20120321A1/es active IP Right Grant
- 2010-04-28 EP EP14194866.1A patent/EP2899191B1/en active Active
- 2010-04-28 SI SI201031548T patent/SI2899191T1/sl unknown
- 2010-04-28 SG SG10201401881QA patent/SG10201401881QA/en unknown
- 2010-04-28 PL PL14194866T patent/PL2899191T3/pl unknown
- 2010-04-28 MX MX2011011534A patent/MX2011011534A/es active IP Right Grant
- 2010-04-28 BR BRPI1016219A patent/BRPI1016219B8/pt not_active IP Right Cessation
-
2011
- 2011-10-21 CO CO11141673A patent/CO6390057A2/es active IP Right Grant
- 2011-10-23 IL IL215803A patent/IL215803A/en active IP Right Grant
- 2011-10-26 DO DO2011000328A patent/DOP2011000328A/es unknown
- 2011-10-27 ZA ZA2011/07878A patent/ZA201107878B/en unknown
- 2011-10-28 CL CL2011002706A patent/CL2011002706A1/es unknown
- 2011-11-15 CR CR20110603A patent/CR20110603A/es unknown
-
2012
- 2012-10-02 US US13/633,230 patent/US8609657B2/en not_active Expired - Fee Related
- 2012-10-02 US US13/633,348 patent/US8586583B2/en not_active Expired - Fee Related
- 2012-10-02 US US13/633,320 patent/US8586590B2/en not_active Expired - Fee Related
-
2013
- 2013-11-25 US US14/088,505 patent/US20140080830A1/en not_active Abandoned
-
2015
- 2015-02-19 SM SM201500043T patent/SMT201500043B/xx unknown
- 2015-05-27 US US14/722,176 patent/US20150328226A1/en not_active Abandoned
-
2016
- 2016-08-02 US US15/225,962 patent/US20170015656A1/en not_active Abandoned
-
2017
- 2017-02-15 US US15/433,010 patent/US20170157136A1/en not_active Abandoned
- 2017-05-05 AR ARP170101175A patent/AR108388A2/es unknown
- 2017-09-27 HR HRP20171450TT patent/HRP20171450T1/hr unknown
- 2017-10-11 CY CY20171101063T patent/CY1119515T1/el unknown
-
2018
- 2018-05-16 US US15/980,778 patent/US20180325911A1/en not_active Abandoned
-
2019
- 2019-02-20 US US16/280,094 patent/US10383879B2/en active Active
- 2019-07-09 US US16/505,769 patent/US10624898B2/en active Active
-
2020
- 2020-03-12 US US16/816,311 patent/US10946025B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33304B1 (fr) | Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase | |
| EA201000113A1 (ru) | Пиразольные соединения | |
| EA201070480A1 (ru) | Ингибиторы с-fms киназы | |
| EA201100391A1 (ru) | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы | |
| EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
| EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| EA201290191A1 (ru) | N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ | |
| EA201500175A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| JO3007B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| MX2009009590A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
| EA201071264A1 (ru) | Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера | |
| EA200901488A1 (ru) | Замещенные имидазолопиридазины, как ингибиторы липидкиназы | |
| EA201300052A1 (ru) | [1,8]нафтиридиновые производные | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| EA201170922A1 (ru) | Производные сульфонамида | |
| NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
| EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| MA35643B1 (fr) | Inhibiteur de cetp d'oxazolidinone bicyclique condensée | |
| EA201100503A1 (ru) | Глюкозидные производные и их применения | |
| EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы |